Maas BiolAB Granted Pan-European Cyclosporin Neuroprotection Patent.Business Editors/Biotechnology Writers BIOWIRE2K ALBUQUERQUE, N.M.--(BUSINESS WIRE)--June 9, 2003 Maas BiolAB has been granted Cyclosporin Neuroprotection patent number 0813420 by the European Patent Office (EPO EPO see erythropoietin. EPO Erythropoietin, see there ). This pan-European patent covers the 400 million people in the 19 European countries of Austria, Belgium, Denmark, France, Germany, Greece, Ireland, Italy, Latvia, Lithuania, Luxembourg, Monaco, Netherlands, Portugal, Slovenia, Spain, Sweden, Switzerland, and the United Kingdom. Cyclosporins were discovered by Maas Scientific Director Eskil Elmer MD, PhD to have new uses as the most effective neuroprotectant drugs across the spectrum of neurological disease models. Cyclosporins protect the brain mitochondria and prevent neuron death in stroke, traumatic brain injury Traumatic brain injury (TBI), traumatic injuries to the brain, also called intracranial injury, or simply head injury, occurs when a sudden trauma causes brain damage. TBI can result from a closed head injury or a penetrating head injury and is one of two subsets of acquired brain , spinal cord injury Spinal Cord Injury Definition Spinal cord injury is damage to the spinal cord that causes loss of sensation and motor control. Description Approximately 10,000 new spinal cord injuries (SCIs) occur each year in the United States. , Alzheimer disease, Parkinson disease, Huntington disease and amyotrophic lateral sclerosis amyotrophic lateral sclerosis (ALS) (ā'mīətrōf`ik, sklĭrō`sĭs) or motor neuron disease, (ALS Als (äls), Ger. Alsen, island, 121 sq mi (313 sq km), Sønderjylland co., S Denmark, in the Lille Bælt, separated from the mainland by the narrow Alensund. ) animal models. The NIH "Not invented here." See digispeak. NIH - The United States National Institutes of Health. is funding multi-center human trials treating traumatic brain injury with cyclosporin. Marcus Keep, CEO of Maas, stated "With the addition of the important European sector, we now have patent coverage in the two primary world markets, North America and the European Union, together nearly 900 million people." Maas BiolAB is a privately held neuropharmaceutical corporation developing cyclosporin formulations and with industry partners discovering novel, improved neuroprotective cyclosporin analogs. NeuroPharma AB is a wholly owned Maas subsidiary in Lund, Sweden. For more information please visit www.maasbiolab.com. Maas BiolAB, LLC 1934 Quail Run Loop NE Albuquerque, NM 87122 USA +1-505-797-1020 tel +1-505-797-1024 fax http://www.maasbiolab.com NeuroPharma AB Magle Stora Kyrkogata 6 223 50 Lund, Sweden Cyclosporin Neuroprotection www.maasbiolab.com |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion